Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Other Operating Expenses (2020 - 2024)

Rani Therapeutics Holdings (RANI) has 3 years of Other Operating Expenses data on record, last reported at $3.7 million in Q4 2024.

  • For Q4 2024, Other Operating Expenses changed N/A year-over-year to $3.7 million; the TTM value through Sep 2025 reached $3.7 million, changed N/A, while the annual FY2024 figure was $3.7 million, N/A changed from the prior year.
  • Other Operating Expenses reached $3.7 million in Q4 2024 per RANI's latest filing, up from -$1000.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $3.7 million in Q4 2024 and bottomed at -$34.0 million in Q4 2020.
  • Average Other Operating Expenses over 3 years is -$6.9 million, with a median of $1.3 million recorded in 2020.